NASDAQ: NMRA - Neumora Therapeutics, Inc. Common Stock

Rentabilité sur six mois: +15.61%
Rendement en dividendes: 0.00%
Secteur: Healthcare

Calendrier des promotions Neumora Therapeutics, Inc. Common Stock

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.

plus de détails
It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. The company was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

IPO date 2023-09-14
ISIN US6409791000
Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://neumoratx.com
Цена ао 11.85
Changement de prix par jour: -0.0882% (11.34)
Changement de prix par semaine: +4.42% (10.85)
Changement de prix par mois: +16.09% (9.76)
Changement de prix sur 3 mois: -12.31% (12.92)
Changement de prix sur six mois: +15.61% (9.8)
Changement de prix par an: -33.9% (17.14)
Evolution du prix sur 3 ans: 0% (11.33)
Evolution du prix sur 5 ans: 0% (11.33)
Evolution des prix sur 10 ans: 0% (11.33)
Evolution des prix depuis le début de l'année: +15.97% (9.77)
Tous les paramètres

Sous-estimation

Nom Signification Grade
P/S 0 0
P/BV 5.77 2
P/E 0 0
EV/EBITDA -12.47 0
Total: 2.25

Efficacité

Nom Signification Grade
ROA, % -47.55 0
ROE, % -50.3 0
Total: 0

Dividendes

Nom Signification Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Devoir

Nom Signification Grade
Debt/EBITDA -0.0279 10
Total: 9.4

Impulsion de croissance

Nom Signification Grade
Rentabilité Revenue, % 0 0
Rentabilité Ebitda, % 96.57 9
Rentabilité EPS, % 127.36 10
Total: 7.8
Plus de détails

Établissements Volume Partager, %
Softbank Group Corporation 7646916 4.81
FMR, LLC 6373129 4.01
MIC Capital Management UK LLP 4460700 2.81
ICONIQ Capital, LLC 3398628 2.14
Wellcome Trust Ltd (the) As Trustee Of The Wellcome Trust 3309123 2.08
Artal Group S.A. 2552702 1.61
EcoR1 Capital, LLC 2071450 1.3
Avidity Partners Management, LP 1990632 1.25
Johnson & Johnson 1849445 1.16
Citadel Advisors Llc 1843291 1.16

ETF Partager, % Rentabilité pour l'année, % Dividendes, %
iShares U.S. Pharmaceuticals ETF 0.41562 6.09 1.97922
iShares Russell 2000 Growth ETF 0.08025 38.04 0.6026
iShares Morningstar Small-Cap ETF 0.01976 391.25 1.60498
iShares Morningstar Small-Cap ETF 0.01976 30.1 1.60498
iShares Russell 3000 ETF 0.00212 24.83 1.43482



Superviseur Titre d'emploi Paiement Année de naissance
Mr. Paul L. Berns Co-Founder & Executive Chairman 1.65M 1967 (58 années)
Mr. Henry O. Gosebruch President, CEO & Director 3.33M 1973 (52 année)
Ms. Carol Suh Co-Founder & COO N/A 1990 (35 années)
Dr. Rajesh Manchanda Ph.D. Chief Technical Operations Officer N/A 1966 (59 années)
Mr. Nicholas Brandon Ph.D. Chief Scientific Officer N/A 1974 (51 année)
Mr. Jason G. Duncan Chief Legal Officer 315k 1974 (51 année)
Mr. Michael Lee Milligan Principal Accounting Officer N/A
Mr. Robert Lenz M.D., Ph.D. Head of Research & Development 770.29k 1971 (54 année)
Dr. Joshua Pinto Ph.D. Chief Financial Officer 876.64k 1985 (40 années)
Dr. Robert Michael Poole FACP, M.D. Co-Founder & Advisor 1957 (68 années)

Adresse: United States, Watertown. MA, 490 Arsenal Way - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://neumoratx.com